{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-015646","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2025-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.366466+00:00","generated_at":"2026-05-27T07:24:37.998703+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Tyra Biosciences appoints Adele M. Gulfo to board; Nina Kjellson resigns","bullets":["Nina Kjellson resigned from board and Compensation Committee effective Jan 29, 2025, not due to disagreement.","Adele M. Gulfo appointed as Class I director and to Compensation Committee effective same date.","Gulfo, 62, former CEO Sumitomo Pharma America Biopharma Commercial Unit (Jul 2023-Oct 2024) and prior roles at Sumitovant, Roivant, Mylan, Pfizer, AstraZeneca.","Gulfo received options for 37,200 shares vesting over 36 months and cash compensation per non-employee director program.","Board determined Gulfo independent under Nasdaq rules; no material transactions with company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-015646","json":"https://secwatch.observer/filing/0001193125-25-015646.json","markdown":"https://secwatch.observer/filing/0001193125-25-015646.md","text":"https://secwatch.observer/filing/0001193125-25-015646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525015646/0001193125-25-015646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525015646/d922700d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T07:24:37.998703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0766397277","claim":"Adele M. Gulfo was appointed as Director at Tyra Biosciences, Inc..","evidence_excerpt":"the Board appointed Adele M. Gulfo as a director of the Board, filling the Class I vacancy on the Board resulting from Ms. Kjellson’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525015646/0001193125-25-015646-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"428912f125","claim":"Nina Kjellson resigned as Director at Tyra Biosciences, Inc..","evidence_excerpt":"Nina Kjellson resigned from the Board and the Compensation Committee of the Board effective as of January 29, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525015646/0001193125-25-015646-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}